1stOncology™: Cancer Intelligence Service – Page 8988 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

On November 22, 2021 Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, reported that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 A.M. EST on November 22, 2021 (Press release, Inspirna, NOV 22, 2021, View Source [SID1234596758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A pre-recorded webcast of the presentation will be available at the time of the presentation and will be available on Inspirna’s website within the News section.

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

On November 22, 2021 Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, reported that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021 (Press release, Portage Biotech, NOV 22, 2021, View Source [SID1234595957]). Dr. Walters will give an overview of Portage’s pipeline and status of current programs, including the company’s lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.

The pre-recorded presentation is available now through the following link (here) as well as on the Investor section of the company’s website at View Source Management will also be hosting 1×1 meetings on November 30 and December 1.

Fresenius Helios acquires oncological center and ophthalmic clinic in Colombia

On November 22, 2021 Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, reported that it has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company’s presence in Colombia (Press release, Fresenius, NOV 22, 2021, View Source [SID1234595954]). The clinics, located in Colombia’s second largest city Medellín, will become part of Quirónsalud’s existing healthcare network in the country, which already comprises six hospitals and ten diagnostic centers.

COA is specialized in the diagnosis and treatment of cancer. It has 75 beds, four operating rooms, and specialized centers for nuclear medicine, radiotherapy and bone marrow transplants. Clínica Clofán is the second largest ophthalmic center in the city, with ten operating rooms and further dedicated facilities for treating even severe ophthalmic diseases and performing complex procedures.

Both clinics offer state-of-the-art medical standards and technology to their patients and are regarded as leading medical facilities with highly renowned physicians. Together they generate sales of around €30 million.

The acquisition is another important step in strengthening Fresenius Helios’ presence in the growing and consolidating healthcare services markets in Latin America.

The transaction is expected to close in the first quarter of 2022, pending anti-trust clearance of the Colombian authorities. Fresenius Helios expects the acquisition to be accretive to Fresenius’ Group net income already in fiscal year 2022.

Flywheel Partners with Roche and Genentech to Accelerate Development of Personalized Healthcare Solutions

On November 22, 2021 Flywheel, the leading cloud-scale informatics platform for biomedical research and collaboration, reported the successful integration of its platform by Roche and Genentech, a member of the Roche Group, for ingestion, classification, standardization, curation and analysis of medical imaging data (Press release, Hoffmann-La Roche, NOV 22, 2021, View Source [SID1234595953]).

The secure, scalable Flywheel platform enables aggregation and management of medical imaging and associated data to accelerate drug discovery. The data is organized and processed with automated pipelines—saving significant time and minimizing the potential for human error in the drug development process. Cost and timeline efficiencies allow researchers to focus on what matters most—bringing life-changing therapies to patients faster. Moreover, Flywheel’s unique approach has enabled multi-site collaboration and development of a customized solution for Roche and Genentech’s needs.

"Manual processes to curate data at the terabyte and petabyte levels are historically costly, time-consuming and prone to human error. With our platform in place, Roche and Genentech researchers can access high-quality images for complex analysis and machine learning, ultimately speeding the development of innovative therapies," said Jim Olson, CEO of Flywheel. "Before using the platform, this level of collaboration and analysis was simply not possible."

"At Roche we envision a future where data, analytics and digital technologies routinely enable more targeted, efficient research and development and more integrated, personalized care," said James Sabry, Head of Roche Pharma Partnering. "The Flywheel platform enables rapid access to highly-curated imaging data, enhancing our ability to answer key scientific questions that are critical to advancing better patient care experiences and outcomes."

Life sciences organizations are making significant investments in digital transformations that foster AI technology in hopes of improving R&D processes and bringing drugs to the market faster. Modern infrastructures are needed to aggregate, curate, and analyze a vast assortment of rich, biomedical data to support these initiatives and enable machine learning, big data analytics, and other strategic data-driven objectives.

Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021

On November 22, 2021 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, reported two poster presentations featuring clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 (Press release, Adagene, NOV 22, 2021, View Source [SID1234595952]).

The conference abstracts are expected to be published on the ESMO (Free ESMO Whitepaper)-IO website on Thursday, December 2, 2021 and posters available on Monday, December 6, 2021 in advance of the hybrid meeting being held virtually and in Geneva, Switzerland from December 8 to 11, 2021.

"These clinical data from two of our ongoing NEObody clinical programs showcase the importance of our pioneering approach to target a unique epitope and reflect the dynamic interactivity between an antibody and antigen," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. "The pharmacodynamic biomarker findings from our ongoing ADG106 trial with the anti-PD-1 toripalimab reinforce the potential synergistic combination for strong T-cell activation. For our novel anti-CTLA-4 program, data from the ongoing dose escalation of ADG116 monotherapy support the robust safety profile and dose dependent T-cell activation in both hot and cold tumors, suggesting potential clinical benefit following our translational studies. Each of these analyses highlights the promise of our tailor-made programs to achieve the fine balance between safety and efficacy – thereby unlocking the full value of some of the most promising yet challenging immuno-oncology targets today."

Details for the poster presentations during ESMO (Free ESMO Whitepaper)-IO 2021 include:

·Title: Assessment of Biomarker Kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab
Presentation Number: 43P

Date: Monday, December 6, 2021

Time: 12:00 Central European Time

·Title: Phase 1 dose-finding study of a novel anti–CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors
Presentation Number: 137P

Date: Monday, December 6, 2021

Time: 12:00 Central European Time

Both the ADG106 and ADG116 programs use Adagene’s innovative NEObody technology, which enables targeting of unique and highly conserved epitopes against a broad range of antigens. These species cross-reactive antibodies not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity translation from preclinical to clinical studies. The company is also developing an anti-CTLA-4 antibody, ADG126, using its SAFEbody precision masking technology.